Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaki R, Matsuura M, Watanabe K, Shiga H, Takatsu N, Bamba S, et al. Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD). Journal of gastroenterology. 2022. 57. 867-878
Matsuoka K, Hisamatsu T, Kim HJ, Ye BD, Arai S, Hoshi M, Yuasa H, Tabira J, Toyoizumi S, Shi N, et al. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. Journal of gastroenterology and hepatology. 2022. 37. 1884-1892
Okabayashi S, Yamazaki H, Yamamoto R, Anan K, Matsuoka K, Kobayashi T, Shinzaki S, Honzawa Y, Kataoka Y, Tsujimoto Y, et al. Certolizumab pegol for maintenance of medically induced remission in Crohn's disease. The Cochrane database of systematic reviews. 2022. 6. CD013747
Matsuoka K, Nagano K, Nagasaki S, Murata Y, Hisamatsu T. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study. BMJ open. 2022. 12. e060081-1892
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, et al. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). Journal of gastroenterology. 2022. 57. 174-184
